EP1968690A1 - Helical electrodes for intramyocardial pacing and sensing - Google Patents

Helical electrodes for intramyocardial pacing and sensing

Info

Publication number
EP1968690A1
EP1968690A1 EP06817078A EP06817078A EP1968690A1 EP 1968690 A1 EP1968690 A1 EP 1968690A1 EP 06817078 A EP06817078 A EP 06817078A EP 06817078 A EP06817078 A EP 06817078A EP 1968690 A1 EP1968690 A1 EP 1968690A1
Authority
EP
European Patent Office
Prior art keywords
lead
electrode
pacing
electrodes
helix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06817078A
Other languages
German (de)
French (fr)
Other versions
EP1968690A4 (en
Inventor
Paul A. Friedman
Charles J. Bruce
Samuel J. Asirvatham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of EP1968690A1 publication Critical patent/EP1968690A1/en
Publication of EP1968690A4 publication Critical patent/EP1968690A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • A61N1/057Anchoring means; Means for fixing the head inside the heart
    • A61N1/0573Anchoring means; Means for fixing the head inside the heart chacterised by means penetrating the heart tissue, e.g. helix needle or hook
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems

Definitions

  • This invention relates to cardiology, and more particularly to cardiac electrodes.
  • Leads are electrical conductors, and often are coated with an outer polymeric covering.
  • the electrical conductors in a pacing lead can be arranged linearly or co-axially.
  • the invention provides for 1) a bipolar helical pacing lead; 2) a steerable sheath or catheter that can be attached to cardiac tissue via an anchor screw, which can be used to maintain the placement of the sheath or catheter, respectively, at a specific intracardiac location; and 3) a method of pacing the right and left ventricles from the atrial- ventricular septum.
  • This invention overcomes limitations with current leads and lead delivery systems. These limitation include the inability to precisely steer, navigate, and actively fix a lead to a desired specific anatomic location; the propensity of current leads to reject far-field electrical signals (e.g., from cardiac structures adjacent to the structure in which the lead is positioned); and the inability of current leads to selectively capture intramyocardial tissue, preventing undesirable stimulation of surrounding tissue.
  • the capability of the present invention to overcome these limitations permits a novel form of pacing (biventricular pacing via the right atrium alone), and enhances many current types of pacing and sensing, particularly those associated with implantable defibrillators. Additionally, the capability to target and fix a therapeutic delivery tool at a precise location within the tissue has many applications outside of cardiovascular medicine.
  • the invention provides an electrical lead.
  • Such an electrical lead generally includes a lead body and at least two electrodes.
  • the lead body has a proximal end and a distal end, and has at least two conductors.
  • the two electrodes are disposed at the distal end of the lead body, and have a proximal end and a distal end.
  • the proximal ends of the electrodes are electrically connected to the distal ends of the conductors.
  • the electrodes comprise an inner electrode and an outer electrode, wherein the outer electrode is helical shaped and has an inside-the-helix surface and an outside-the-helix surface.
  • the inner electrode is linear and can be partially coated with a non-conductive material.
  • the inner electrode is helical shaped and has an inside-the-helix surface and an outside- the-helix surface.
  • the inside-the-helix surface of the outer electrode is coated with a non-conductive material, or the outside-the-helix surface of the inner electrode is coated with a non-conductive material.
  • the outside-the-helix surface of the outer electrode is coated with a non-conductive material, or the inside-the-helix surface of the inner electrode is coated with a non-conductive material.
  • the inner electrode and the outer electrode are co-axial at the proximal ends.
  • the overall length of the electrical lead can be, without limitation, about 3 mm to about 7 mm.
  • the conductors are co-axial with one another, or are parallel to one another.
  • the inner electrode and the outer electrode are bipolar.
  • Figure 1 is an image of one embodiment of a bipolar pacing lead.
  • Figure 2 is an image of another embodiment of a bipolar pacing lead.
  • Figure 3 shows additional embodiments of a bipolar pacing lead.
  • Figure 4A is a side view of one embodiment of a steerable sheath.
  • Figure 4B is a cross-sectional view of the steerable sheath shown in Figure 4 A (at the dotted line).
  • left and/or right ventricle from the right atrium would provide a number of benefits. There would be no need to cross the tricuspid valve with a pacing lead, preventing the problem of valvular regurgitation or damage, and permitting use in the setting of a mechanical valve. Additionally, left ventricular pacing has been shown effective in the treatment of heart failure, but deploying a lead for left ventricular pacing is technically challenging in that lead placement requires entering the coronary sinus and its tributaries or, for epicardial placement, surgical thoracotomy. Thus, the ability to pace the leftventricle in particular via a lead_positioned in the right atrium would be of tremendous clinical benefit.
  • the anatomical area best suited for this approach is the atrioventricular septum.
  • the atrioventricular septum is a small area where the septum of the right atrium is contiguous with the left ventricular septum. It is a unique region of the heart in which there is juxtaposition of left ventricular, right ventricular, and right atrial myocytes.
  • the lead can not only sense activity across both ventricles and the right atrium, but also permit capture ofboth ventricles and, if positioned properly, the right atrium.
  • a tool for delivery of a pacing lead to a precise location is required, and a lead capable of intramyocardial stimulation and sensing is necessary.
  • pacing and defibrillation leads are directed to desired locations with the use of stylets that can be custom curved at the time of surgery or over guidewires when leads are placed in the coronary venous system.
  • Active steering to permit precise intra-chamber positioning has, heretoforth, not been feasible.
  • This disclosure describes both a tool for precise delivery of therapy (including placement of an electrical lead) and a novel pacing lead suitable for use intramyocardially.
  • an electrical lead 1 generally includes a lead body 10 having a proximal 12 and a distal 14 end.
  • the lead body 10 typically has a lumen (1), through which at least two conductors 20 run longitudinally L.
  • the distal end 14 of the lead body 10 has at least two electrodes 30, each having a proximal 32 and a distal 34 end.
  • the proximal end 32 of each electrode 30 is electrically connected to the distal end 24 of a corresponding conductor 20.
  • an electrode 30 maybe the exposed distal end 24 of the conductor 20.
  • the electrical lead 1 described herein has at least an inner electrode 36 and an outer electrode 38.
  • the inner and outer electrodes can be coaxial at their proximal ends.
  • Either or both the inner electrode 36 or the outer electrode 38 can have a helical shape.
  • the helical shape of an electrode 30 results in the electrode having a surface that is substantially on the inside of the helix and a surface that is substantially on the outside of the helix.
  • both the inner electrode 36 and the outer electrode 38 have a helical shape (i.e., a helix-within-a-helix configuration).
  • the helices of the inner electrode 36 and the outer electrode 38 need not have the same helical pitch (see, also, Figure 3A). Although the helices in Figure 1 are both shown as turning clockwise, either or both of the helices can be configured to turn counterclockwise. Therefore, a helix-within-a-helix configuration results in each electrode having an inside-the-helix surface and an outside-the-helix surface.
  • Figure 2 shows another embodiment of an electrical lead 1 having an inner electrode 36 and an outer electrode 38.
  • the outer electrode 38 has a helical shape while the inner electrode 36 is linear.
  • the inner linear electrode 36 is shorter than the outer helical electrode 38. In certain applications, however, it may be desirable to have the inner linear electrode extend beyond the length of the outer helical electrode, hi some embodiments, the inner linear electrode 36 can be retractable and/or deployable.
  • an electrical lead as described herein can have other configurations. See, for example, Figure 3 for additional embodiments of an electrical lead.
  • an electrical lead can have a single helix with one pole at the proximal end, the other pole at the distal end, and insulative material in between the two poles.
  • an electrical lead can have two helices that have substantially the same pitch and therefore, are essentially adjacent to each other.
  • Figure 3D shows an embodiment similar to that shown in Figure 1, however, in the embodiment shown in Figure 3D, both the inner electrode and the other electrode can be entirely insulated, with the insulation removed at positions along the electrodes where the inner helix and the other helix are farthest apart.
  • Figure 3B shows an embodiment of a bipolar pacing lead in which both leads are helically shaped but are separated (i.e., do not have a helix- within-a-helix configuration).
  • either electrode can be insulated (e.g., by coating with a non-conductive material) to control (e.g., focus) the direction of dispersement of electromagnetic force.
  • the inside surface or the outside surface of either electrode can be insulated.
  • either or both electrodes can be insulated in a pattern that prevents contact but allows current flow.
  • Figure 2 In which a 'swiss-cheese' pattern of insulation is shown.
  • the openings or holes may be elongated so as to create a multi-slit or multi-slot pattern of insulation.
  • One or more electrodes that are configured to optimize the direction of dispersement of electromagnetic force allows for a greater chance at capturing the heart.
  • Each electrode itself can be unipolar or bipolar, or the pair of electrodes (i.e., the electrical lead) can be unipolar or bipolar.
  • the inner electrode can be the cathode and the other electrode can be the anode, or vice versa.
  • the electrodes also can have different lengths with, for example, the inner electrode having a longer length than the outer electrode (see, for example, Figure 3C).
  • the inner electrode can be helical and have an insulator at its midpoint, while the outer electrode reaches only to the midpoint of the inner electrode.
  • the energy would flow from helix to helix where the two electrodes overlap and from the tip of the inner electrode back to the outer electrode where they don't overlap.
  • fibrosis often develops at the site of an electrode and that long-term pacing and sensing is adversely affected by the fibrosis.
  • This has been overcome with standard leads by using, for example, steroid-eluting tips or collars to mitigate the inflammatory response.
  • the same or similar technology can be utilized with the leads described herein.
  • steroid-containing pellets or the like can be deposited within such openings or cavities and, therefore, applied intramyocardially.
  • lntramyocardial pacing permits very localized cardiac excitation without far-field capture.
  • the co-axial and helical shaped features of the electrodes described herein allow for intramyocardial pacing in thin tissue. For example, two electrodes positioned co-axially obviates the need for longer electrodes that are required by sequential electrodes, hi addition, an electrode having a helical shape has a shorter effective length than its actual linear length. Therefore, a helical shaped electrode can be used to intra-myocardially stimulate thinner regions of the myocardium such as the atria or the septum.
  • a normal septum can be from about 8 mm to about 15 mm in thickness, while a diseased septum may be 6 mm to 8 mm thick. It is one object of the helical electrical lead described herein to provide a significant amount of effective surface area while having a small overall length (e.g., 3 mm, 4 mm, 5 mm, 6 mm, or 7 mm).
  • a helical electrical lead as described herein also can be configured to have a larger overall length (e.g., 10 mm, 15 mm, 20 mm, 25 mm, 30 mm) to, for example, excite ventricular myocardium from the atrioventricular septum.
  • a larger overall length e.g. 10 mm, 15 mm, 20 mm, 25 mm, 30 mm
  • ⁇ itramyocardial pacing at the intraventricular septum can excite left- ventricular myocardium, which would permit left ventricular pacing with the lead positioned in the right atrium.
  • pacing of the intraventricular septum at low output may allow for more rapid conduction to the remainder of the left ventricle (owing to the fibro- orientation at this pacing site) while pacing at a higher output may directly capture the penetrating His bundle. Either or both of these mechanisms may achieve a relatively rapid conduction to the left ventricle and, since the left ventricular myocardium is stimulated, may allow for right-sided cardiac resynchronization.
  • ventricular pacing performed via the atrioventricular route avoids crossing the tricuspid valve.
  • the presence of a lead across the tricuspid valve has been a factor associated with clinically significant tricuspid regurgitation and avoiding valve insult appears to be desirable, hi addition, pacing that requires the use of a high output (e.g., cardiac contractility modulation) must capture left ventricular myocardium without phrenic nerve stimulation, which is possible using the leads described herein.
  • an electrical lead as described herein can be pushed through the right atrial appendage into the right ventricle, and the helical electrode can be screwed into the right ventricle for right ventricle pacing.
  • the lead body would remain in the right atrium, but the helical electrode would be screwed through the right atrial appendage and entirely into the ventricular muscle tissue.
  • An electrical lead as described herein also would be advantageous for use as an atrial lead in pacemakers and implantable defibrillators.
  • the atrial leads of pacemakers and implantable defibrillators are very susceptible to far-field sensing of non-atrial signals, which often results in errors in rhythm analysis.
  • the bipolar helical electrode described herein can be placed entirely within the myocardium rather than one pole in and one pole out or a bipolar lead partially in, to prevent far-field capture and sensing.
  • a steerable sheath and a steerable catheter are described herein.
  • a steerable sheath such as that described herein allows for active fixation once it is positioned against the target tissue. Fixation of the sheath permits delivery of therapy such as permanent pacing leads to the desired target without risk of tip displacement.
  • the steerable sheath can be "unfixed,” leaving behind aTprecisely placed permanent leadTor it can be left in place to provide, for example, delivery of additional therapy.
  • a steerable sheath 101 or a steerable catheter 101 each have a body 105 having a proximal portion 107 and a distal portion 109 along a longitudinal axis L.
  • the sheeth or catheter body 105 is generally tubular and can contain a central lumen (1).
  • the proximal 107 and distal 109 portions of the steerable sheath or catheter 101 can be integrally formed from a biocompatible material having requisite strength and flexibility for introducing and advancing the sheath or catheter into the vasculature of an individual.
  • Appropriate materials are well known in the art and generally include polyamides such as, for example a woven material available from DuPont under the trade name DACRON®.
  • the steerable sheath or catheter 101 uses longitudinal pins or wires 115 arranged radially around the sheath or catheter to control tip motion (see Figure 4B).
  • Each longitudinal pin 115 has a proximal end 117 and a distal end 119.
  • the distal ends 119 are attached to the distal portion 109 of the sheath or catheter, and the proximal end 117 of each pin has a pin-control 121.
  • the distal end of the sheath or catheter 109 can be manipulated for precise navigation by a user.
  • a steerable sheath or catheter 101 is not limited by the number of longitudinal pins 115.
  • the precise number and location of the longitudinal pins 115 will depend on the amount of steerability desired as well as the flexibility of the material used to make the sheath or catheter body 105.
  • a steerable sheath or steerable catheter 101 can include at least one sensing or imaging component (not shown).
  • the sensing or imaging component can be, without limitation, an ultrasound sensor, a fluoroscopy sensor, a pacing and sensing electrode, and/or a pressure sensor.
  • an operator can examiner or determine blood flow and/or supply, an electrogram of the region (e.g., the septum), and/or pressure differences (e.g., in the atrium versus the ventricle).
  • Precise location can also be achieved by extraneous imaging using, for example, fluoroscopy, magnetic guidance, and/or echocardiography. For example, for placement into the atrioventricular septum, a location havinglfpressure signal indicative of the atrium and an electrical myocardial signal indicative of the right ventricle is identified.
  • an anchor screw 125 at the distal portion 109 of the sheath or catheter body 105 can be used to fix the distal portion 109 of the sheath or catheter 101 at the desired location within the heart.
  • Fixation of the distal portion 109 of a sheath via such an anchor screw 125 provides a working channel (or conduit) to the desired location to deliver a pacing lead (e.g., the helical electrode described herein) or other tool (e.g., ablative tools), or to perform tasks such as delivering a therapeutic compound such as drugs or cells or removing a biopsy, while fixation of the distal portion (e.g., ablative therapy) to be delivered to a precise location without requiring new placement of the catheter each time.
  • a pacing lead e.g., the helical electrode described herein
  • other tool e.g., ablative tools
  • the anchor screw can be an active electrode to permit sensing and/or stimulation (e.g., to determine the responsiveness of the myocardial tissue prior to permanent lead deployment).
  • a steerable sheath having an anchor screw also can be used in procedures such as the Cardiac Contractility Modulation (CCM) in which specific cardiac locations need to be identified.
  • CCM Cardiac Contractility Modulation
  • a steerable sheath or steerable catheter 101 can have one or more control knobs 135 at the proximal portion 107 to screw an anchor screw 125 or a helical electrode 30 in or out of tissue.
  • a control knob 135 By turning a control knob 135, for example, clockwise, an operator can screw an anchor screw 125 on a steerable sheath or steerable catheter 101 into tissue at the desired location, or similarly, screw a helical electrode 30 into tissue.
  • a control knob 135 for example, counterclockwise, an anchor screw 125 on a steerable sheath or steerable catheter 101 or a helical electrode 30 can be unscrewed from the tissue.
  • sheath and catheter described herein having an anchor screw at the distal end is described with respect to cardiac applications, it's use is not to be limited in any way.
  • a sheath or a catheter having an anchor screw for fixing its position can be used in, for example, endoscopy in the field of gastrointestinal (GI), urology, or other appropriate fields in medicine or research, hraccordance with the present invention, there may be employed conventional cardiology techniques within the skill of the art. Such techniques are explained fully in the literature.
  • the aim of the experiment was to: 1) determine whether intramyocardial pacing and sensing is feasible and 2) compare the sensed signals and pacing thresholds of the novel intramyocardial lead with a standard commercially available pacing lead.
  • epicardial pacing and sensing was undertaken in a carefully controlled manner.
  • Epicardial (rather than endocardial) lead function was initially assessed due to the limited maneuverability of the prototype leads, which, it was anticipated, would limit reliable endocardial positioning.
  • the lead was inserted into the myocardium under direct vision; pacing and sensing was performed at three epicardial locations (right ventricle, lateral left ventricle, and right atrial appendage).
  • the lead was connected to a standard pacing electrophysiology workstation for recording electrograms. Particular attention was paid to defining both atrial and ventricular signals if present and their amplitude. Pacing was performed using a portable pulse generator capable of delivering up to 20 mA current (Medtronic, Inc, Minneapolis, MN). Thresholds were assessed at both polarities (cathode central electrode, and cathode helix, for intramyocaridial lead). Evidence of extracardiac stimulation was noted, and during the procedure, any arrythmias or ventricular ectopy were noted. After pacing and sensing experiments were completed, the lead was extracted by employing counterclockwise rotation of the entire lead, and the lead tip and cardiac tissue was examined for damage.
  • the lead was then inserted via the internal jugular vein and advanced into the right ventricular apex under fluoroscopic guidance.
  • the electrode tip was screwed into the endocardium by rotation of the entire lead. After confirming a right ventricular apical location, right ventricular endocardial pacing and sensing was then performed with the intramyocardial lead.
  • Ventricular pacing and sensing lead function are summarized in Table 1.
  • the average R wave at ventricular sites was 7.2 mV, compared to an average R wave of 8.4 mV for the standard active fixation lead placed at identical sites.
  • the average pacing threshold was 0.7 mA at 0.2 msec for the novel lead compared to 1.1 mA for the standard lead.
  • Far field P waves were not recorded on the novel lead; the mean far-field P-wave on the standard lead was 0.7 mV.
  • phrenic stimulation was seen at threshold (cathode distal) and at 3 mA (cathode proximal electrode). No phrenic stimulation was seen despite outputs up to 20 mA and sites located 3-5 mm from the phrenic nerve.
  • the results of lead placement at the right atrial appendage base are shown in Table 2.
  • the average atrial electrogram for the intramyocardial lead measured 1.7 mV; far-field R-waves were not present (amplitude 0 mV).
  • the atrial electrogram amplitude average measured 1.9 mV; the average far-field R-wave was 1.6 mV.
  • Phrenic stimulation occurred with both polarities using the standard lead, and with neither polarity using the novel intramyocardial lead.

Abstract

The invention provides for an electrical lead , s steerable sheath and a steerable catheter, a sheath and a catheter that attach to cardiac tissue via an anchor screw (38), and a method of pacing, particularly via the atrioventricular septum.

Description

HELICAL ELECTRODES FOR INTRAMYOCARDIAL PACING AND SENSING
TECHNICAL FIELD
This invention relates to cardiology, and more particularly to cardiac electrodes.
BACKGROUND
Various leads have been developed for pacing the different chambers of the heart. Leads are electrical conductors, and often are coated with an outer polymeric covering. The electrical conductors in a pacing lead can be arranged linearly or co-axially.
SUMMARY
The invention provides for 1) a bipolar helical pacing lead; 2) a steerable sheath or catheter that can be attached to cardiac tissue via an anchor screw, which can be used to maintain the placement of the sheath or catheter, respectively, at a specific intracardiac location; and 3) a method of pacing the right and left ventricles from the atrial- ventricular septum.
This invention overcomes limitations with current leads and lead delivery systems. These limitation include the inability to precisely steer, navigate, and actively fix a lead to a desired specific anatomic location; the propensity of current leads to reject far-field electrical signals (e.g., from cardiac structures adjacent to the structure in which the lead is positioned); and the inability of current leads to selectively capture intramyocardial tissue, preventing undesirable stimulation of surrounding tissue. The capability of the present invention to overcome these limitations permits a novel form of pacing (biventricular pacing via the right atrium alone), and enhances many current types of pacing and sensing, particularly those associated with implantable defibrillators. Additionally, the capability to target and fix a therapeutic delivery tool at a precise location within the tissue has many applications outside of cardiovascular medicine. In one aspect, the invention provides an electrical lead. Such an electrical lead generally includes a lead body and at least two electrodes. Typically, the lead body has a proximal end and a distal end, and has at least two conductors. Usually, the two electrodes are disposed at the distal end of the lead body, and have a proximal end and a distal end. Generally, the proximal ends of the electrodes are electrically connected to the distal ends of the conductors. Typically, the electrodes comprise an inner electrode and an outer electrode, wherein the outer electrode is helical shaped and has an inside-the-helix surface and an outside-the-helix surface. In certain embodiments, the inner electrode is linear and can be partially coated with a non-conductive material. In other embodiments, the inner electrode is helical shaped and has an inside-the-helix surface and an outside- the-helix surface. In some embodiments, the inside-the-helix surface of the outer electrode is coated with a non-conductive material, or the outside-the-helix surface of the inner electrode is coated with a non-conductive material. Li other embodiments, the outside-the-helix surface of the outer electrode is coated with a non-conductive material, or the inside-the-helix surface of the inner electrode is coated with a non-conductive material. In still other embodiments, the inner electrode and the outer electrode are co-axial at the proximal ends. The overall length of the electrical lead can be, without limitation, about 3 mm to about 7 mm. In different embodiments, the conductors are co-axial with one another, or are parallel to one another. In yet other embodiments, the inner electrode and the outer electrode are bipolar.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the drawings and detailed description, and from the claims.
DESCRIPTION OFDRAWINGS
Figure 1 is an image of one embodiment of a bipolar pacing lead. Figure 2 is an image of another embodiment of a bipolar pacing lead. Figure 3 shows additional embodiments of a bipolar pacing lead. Figure 4A is a side view of one embodiment of a steerable sheath. Figure 4B is a cross-sectional view of the steerable sheath shown in Figure 4 A (at the dotted line).
Like reference symbols in the various drawings indicate like elements.
DETAILED DESCRIPTION
The ability to pace the left and/or right ventricle from the right atrium would provide a number of benefits. There would be no need to cross the tricuspid valve with a pacing lead, preventing the problem of valvular regurgitation or damage, and permitting use in the setting of a mechanical valve. Additionally, left ventricular pacing has been shown effective in the treatment of heart failure, but deploying a lead for left ventricular pacing is technically challenging in that lead placement requires entering the coronary sinus and its tributaries or, for epicardial placement, surgical thoracotomy. Thus, the ability to pace the leftventricle in particular via a lead_positioned in the right atrium would be of tremendous clinical benefit. The anatomical area best suited for this approach is the atrioventricular septum. The atrioventricular septum is a small area where the septum of the right atrium is contiguous with the left ventricular septum. It is a unique region of the heart in which there is juxtaposition of left ventricular, right ventricular, and right atrial myocytes. By positioning a lead in this area, the lead can not only sense activity across both ventricles and the right atrium, but also permit capture ofboth ventricles and, if positioned properly, the right atrium. In order to accomplish this, a tool for delivery of a pacing lead to a precise location is required, and a lead capable of intramyocardial stimulation and sensing is necessary. Currently, pacing and defibrillation leads are directed to desired locations with the use of stylets that can be custom curved at the time of surgery or over guidewires when leads are placed in the coronary venous system. Active steering to permit precise intra-chamber positioning has, heretoforth, not been feasible. This disclosure describes both a tool for precise delivery of therapy (including placement of an electrical lead) and a novel pacing lead suitable for use intramyocardially.
Electrical Lead
The term lead or electrical lead as used herein refers to an indewelling electrode for electrical stimulation of tissue. Electrical stimulation can be for, without limitation, pacing, defibrillation, cardiac contraction modulation, sub- threshhold stimulation, or any other type of electrical therapy. With reference to Figure 1, an electrical lead 1 generally includes a lead body 10 having a proximal 12 and a distal 14 end. The lead body 10 typically has a lumen (1), through which at least two conductors 20 run longitudinally L. The distal end 14 of the lead body 10 has at least two electrodes 30, each having a proximal 32 and a distal 34 end. The proximal end 32 of each electrode 30 is electrically connected to the distal end 24 of a corresponding conductor 20. In some embodiments, an electrode 30 maybe the exposed distal end 24 of the conductor 20.
With reference to Figures 1, 2 and 3, the electrical lead 1 described herein has at least an inner electrode 36 and an outer electrode 38. In some embodiments, the inner and outer electrodes can be coaxial at their proximal ends. Either or both the inner electrode 36 or the outer electrode 38 can have a helical shape. The helical shape of an electrode 30 results in the electrode having a surface that is substantially on the inside of the helix and a surface that is substantially on the outside of the helix. In the embodiment shown in Figure 1, both the inner electrode 36 and the outer electrode 38 have a helical shape (i.e., a helix-within-a-helix configuration). As shown in Figure 1, the helices of the inner electrode 36 and the outer electrode 38 need not have the same helical pitch (see, also, Figure 3A). Although the helices in Figure 1 are both shown as turning clockwise, either or both of the helices can be configured to turn counterclockwise. Therefore, a helix-within-a-helix configuration results in each electrode having an inside-the-helix surface and an outside-the-helix surface. Figure 2 shows another embodiment of an electrical lead 1 having an inner electrode 36 and an outer electrode 38. In Figure 2, the outer electrode 38 has a helical shape while the inner electrode 36 is linear. In the embodiment shown in Figure 2, the inner linear electrode 36 is shorter than the outer helical electrode 38. In certain applications, however, it may be desirable to have the inner linear electrode extend beyond the length of the outer helical electrode, hi some embodiments, the inner linear electrode 36 can be retractable and/or deployable.
In addition to a helix-within-a-helix configuration and a linear-within-a- helix configuration, an electrical lead as described herein can have other configurations. See, for example, Figure 3 for additional embodiments of an electrical lead. For example, an electrical lead can have a single helix with one pole at the proximal end, the other pole at the distal end, and insulative material in between the two poles. In addition, an electrical lead can have two helices that have substantially the same pitch and therefore, are essentially adjacent to each other. Figure 3D shows an embodiment similar to that shown in Figure 1, however, in the embodiment shown in Figure 3D, both the inner electrode and the other electrode can be entirely insulated, with the insulation removed at positions along the electrodes where the inner helix and the other helix are farthest apart. Figure 3B shows an embodiment of a bipolar pacing lead in which both leads are helically shaped but are separated (i.e., do not have a helix- within-a-helix configuration).
Any portion of either electrode can be insulated (e.g., by coating with a non-conductive material) to control (e.g., focus) the direction of dispersement of electromagnetic force. For example, the inside surface or the outside surface of either electrode can be insulated. In addition, either or both electrodes can be insulated in a pattern that prevents contact but allows current flow. One example is shown in Figure 2, in which a 'swiss-cheese' pattern of insulation is shown. Alternatively, the openings or holes may be elongated so as to create a multi-slit or multi-slot pattern of insulation. One or more electrodes that are configured to optimize the direction of dispersement of electromagnetic force allows for a greater chance at capturing the heart.
Each electrode itself can be unipolar or bipolar, or the pair of electrodes (i.e., the electrical lead) can be unipolar or bipolar. For example, in a bipolar embodiment, the inner electrode can be the cathode and the other electrode can be the anode, or vice versa. The electrodes also can have different lengths with, for example, the inner electrode having a longer length than the outer electrode (see, for example, Figure 3C). hi one embodiment, for example, the inner electrode can be helical and have an insulator at its midpoint, while the outer electrode reaches only to the midpoint of the inner electrode. In this embodiment, the energy would flow from helix to helix where the two electrodes overlap and from the tip of the inner electrode back to the outer electrode where they don't overlap. It is known in the art that fibrosis often develops at the site of an electrode and that long-term pacing and sensing is adversely affected by the fibrosis. This has been overcome with standard leads by using, for example, steroid-eluting tips or collars to mitigate the inflammatory response. The same or similar technology can be utilized with the leads described herein. In cases in which the insulating material coating or deposited on an electrode contains openings or cavities, steroid-containing pellets or the like can be deposited within such openings or cavities and, therefore, applied intramyocardially. lntramyocardial pacing permits very localized cardiac excitation without far-field capture. The co-axial and helical shaped features of the electrodes described herein allow for intramyocardial pacing in thin tissue. For example, two electrodes positioned co-axially obviates the need for longer electrodes that are required by sequential electrodes, hi addition, an electrode having a helical shape has a shorter effective length than its actual linear length. Therefore, a helical shaped electrode can be used to intra-myocardially stimulate thinner regions of the myocardium such as the atria or the septum.
Previously described bipolar and/or helical pacing leads would be too long and would likely perforate thinner tissues such as the septum. By way of example, a normal septum can be from about 8 mm to about 15 mm in thickness, while a diseased septum may be 6 mm to 8 mm thick. It is one object of the helical electrical lead described herein to provide a significant amount of effective surface area while having a small overall length (e.g., 3 mm, 4 mm, 5 mm, 6 mm, or 7 mm). It is noted, however, that a helical electrical lead as described herein also can be configured to have a larger overall length (e.g., 10 mm, 15 mm, 20 mm, 25 mm, 30 mm) to, for example, excite ventricular myocardium from the atrioventricular septum. ϋitramyocardial pacing at the intraventricular septum can excite left- ventricular myocardium, which would permit left ventricular pacing with the lead positioned in the right atrium. Without being bound by any particular mechanism, pacing of the intraventricular septum at low output may allow for more rapid conduction to the remainder of the left ventricle (owing to the fibro- orientation at this pacing site) while pacing at a higher output may directly capture the penetrating His bundle. Either or both of these mechanisms may achieve a relatively rapid conduction to the left ventricle and, since the left ventricular myocardium is stimulated, may allow for right-sided cardiac resynchronization.
Another potential benefit of intramyocardial septal pacing is that ventricular pacing performed via the atrioventricular route avoids crossing the tricuspid valve. The presence of a lead across the tricuspid valve has been a factor associated with clinically significant tricuspid regurgitation and avoiding valve insult appears to be desirable, hi addition, pacing that requires the use of a high output (e.g., cardiac contractility modulation) must capture left ventricular myocardium without phrenic nerve stimulation, which is possible using the leads described herein.
The use of small electrodes has been desirable since stimulation requires less energy, thereby saving battery life. Size reduction of electrodes, however, has been limited by diminution of the sensed electrogram as electrode size is reduced. It was determined herein that using electrodes as described herein overcomes this limitation, since acceptable electrogram amplitude and pacing thresholds were both present. The absence of stimulation of adjacent tissues with these leads might increase placement options. It would be understood by those of skill in the art that although the electrical lead described herein is extremely well-suited for septal pacing, its use is not limited to the septum and it can be used anywhere in the heart or other tissue where electrical stimulation is required. For example, an electrical lead as described herein can be pushed through the right atrial appendage into the right ventricle, and the helical electrode can be screwed into the right ventricle for right ventricle pacing. For this application, the lead body would remain in the right atrium, but the helical electrode would be screwed through the right atrial appendage and entirely into the ventricular muscle tissue. An electrical lead as described herein also would be advantageous for use as an atrial lead in pacemakers and implantable defibrillators. The atrial leads of pacemakers and implantable defibrillators are very susceptible to far-field sensing of non-atrial signals, which often results in errors in rhythm analysis. The bipolar helical electrode described herein can be placed entirely within the myocardium rather than one pole in and one pole out or a bipolar lead partially in, to prevent far-field capture and sensing.
Steerable Sheath or Catheter
A steerable sheath and a steerable catheter are described herein. Uniquely, a steerable sheath such as that described herein allows for active fixation once it is positioned against the target tissue. Fixation of the sheath permits delivery of therapy such as permanent pacing leads to the desired target without risk of tip displacement. The steerable sheath can be "unfixed," leaving behind aTprecisely placed permanent leadTor it can be left in place to provide, for example, delivery of additional therapy.
With respect to Figure 4A, a steerable sheath 101 or a steerable catheter 101 each have a body 105 having a proximal portion 107 and a distal portion 109 along a longitudinal axis L. The sheeth or catheter body 105 is generally tubular and can contain a central lumen (1). The proximal 107 and distal 109 portions of the steerable sheath or catheter 101 can be integrally formed from a biocompatible material having requisite strength and flexibility for introducing and advancing the sheath or catheter into the vasculature of an individual. Appropriate materials are well known in the art and generally include polyamides such as, for example a woven material available from DuPont under the trade name DACRON®.
The steerable sheath or catheter 101 uses longitudinal pins or wires 115 arranged radially around the sheath or catheter to control tip motion (see Figure 4B). Each longitudinal pin 115 has a proximal end 117 and a distal end 119. The distal ends 119 are attached to the distal portion 109 of the sheath or catheter, and the proximal end 117 of each pin has a pin-control 121. By pushing or pulling on one or more of the pin-controls 121, the distal end of the sheath or catheter 109 can be manipulated for precise navigation by a user. A steerable sheath or catheter 101 is not limited by the number of longitudinal pins 115. The precise number and location of the longitudinal pins 115 will depend on the amount of steerability desired as well as the flexibility of the material used to make the sheath or catheter body 105.
In order to locate the correct anatomical location for placing an electrode, a steerable sheath or steerable catheter 101 can include at least one sensing or imaging component (not shown). The sensing or imaging component can be, without limitation, an ultrasound sensor, a fluoroscopy sensor, a pacing and sensing electrode, and/or a pressure sensor. Using such sensing and/or imaging components, an operator can examiner or determine blood flow and/or supply, an electrogram of the region (e.g., the septum), and/or pressure differences (e.g., in the atrium versus the ventricle). Precise location can also be achieved by extraneous imaging using, for example, fluoroscopy, magnetic guidance, and/or echocardiography. For example, for placement into the atrioventricular septum, a location havinglfpressure signal indicative of the atrium and an electrical myocardial signal indicative of the right ventricle is identified.
Once the desired location within the heart is located, an anchor screw 125 at the distal portion 109 of the sheath or catheter body 105 can be used to fix the distal portion 109 of the sheath or catheter 101 at the desired location within the heart. Fixation of the distal portion 109 of a sheath via such an anchor screw 125 provides a working channel (or conduit) to the desired location to deliver a pacing lead (e.g., the helical electrode described herein) or other tool (e.g., ablative tools), or to perform tasks such as delivering a therapeutic compound such as drugs or cells or removing a biopsy, while fixation of the distal portion (e.g., ablative therapy) to be delivered to a precise location without requiring new placement of the catheter each time. In some embodiments, the anchor screw can be an active electrode to permit sensing and/or stimulation (e.g., to determine the responsiveness of the myocardial tissue prior to permanent lead deployment). A steerable sheath having an anchor screw also can be used in procedures such as the Cardiac Contractility Modulation (CCM) in which specific cardiac locations need to be identified. See, for example, Sabbah et al., 2001, Heart Fail. Rev., 6:45-53; and Mohri et al., 2002, Am. J. Physiol. Heart Ore. Physiol., 282:H1642-7.
A steerable sheath or steerable catheter 101 can have one or more control knobs 135 at the proximal portion 107 to screw an anchor screw 125 or a helical electrode 30 in or out of tissue. By turning a control knob 135, for example, clockwise, an operator can screw an anchor screw 125 on a steerable sheath or steerable catheter 101 into tissue at the desired location, or similarly, screw a helical electrode 30 into tissue. Similarly, by turning a control knob 135, for example, counterclockwise, an anchor screw 125 on a steerable sheath or steerable catheter 101 or a helical electrode 30 can be unscrewed from the tissue. Although the sheath and catheter described herein having an anchor screw at the distal end is described with respect to cardiac applications, it's use is not to be limited in any way. A sheath or a catheter having an anchor screw for fixing its position can be used in, for example, endoscopy in the field of gastrointestinal (GI), urology, or other appropriate fields in medicine or research, hraccordance with the present invention, there may be employed conventional cardiology techniques within the skill of the art. Such techniques are explained fully in the literature.
10 EXAMPLES
Example 1 — Intramyocardial Pacing and Sensing Lead Design
Specially constructed leads with two distal intramyocardial electrodes made of an external helix and a central pin were used for these experiments (Figure 2). The helix length was 5 mm or 7 mm and constructed of 0.012" wire. The inner electrode was 2/3r the length of the outer helix, and constructed of 0.009" wire. In order to minimize the risk of electrical shorting via mechanical contact between the two electrodes, the inner electrode was partially insulated with 0.001" polyimide tubing into which 4 (5 mm lead) or 6 (7 mm lead) 0.01" x 0.20" ports were created. The distal electrodes were non-retractable, and actively fixated by rotation of the entire lead body.
Example 2 — Animal Preparation
Two mongrel dogs weight were placed under general anesthesia and mechanically ventilated. Arterial blood pressure, and surface electrocardiography was continuously recorded. The right internal jugular was cannulated with a 9 Fr sheath. A median sternotomy was performed and the pericardium retracted.
Example 3 — Experimental Procedure
The aim of the experiment was to: 1) determine whether intramyocardial pacing and sensing is feasible and 2) compare the sensed signals and pacing thresholds of the novel intramyocardial lead with a standard commercially available pacing lead. In the first experiment, epicardial pacing and sensing was undertaken in a carefully controlled manner. Epicardial (rather than endocardial) lead function was initially assessed due to the limited maneuverability of the prototype leads, which, it was anticipated, would limit reliable endocardial positioning. The lead was inserted into the myocardium under direct vision; pacing and sensing was performed at three epicardial locations (right ventricle, lateral left ventricle, and right atrial appendage). The lead was connected to a standard pacing electrophysiology workstation for recording electrograms. Particular attention was paid to defining both atrial and ventricular signals if present and their amplitude. Pacing was performed using a portable pulse generator capable of delivering up to 20 mA current (Medtronic, Inc, Minneapolis, MN). Thresholds were assessed at both polarities (cathode central electrode, and cathode helix, for intramyocaridial lead). Evidence of extracardiac stimulation was noted, and during the procedure, any arrythmias or ventricular ectopy were noted. After pacing and sensing experiments were completed, the lead was extracted by employing counterclockwise rotation of the entire lead, and the lead tip and cardiac tissue was examined for damage.
Li a second experiment, pacing and sensing function was undertaken in the same manner as before and also compared to that of a standard active fixation pacemaker lead (Flextend Model 4088, Boston Scientific Cardiac
Rhythm Management, St. Paul, MN). Additionally, the lead was then inserted via the internal jugular vein and advanced into the right ventricular apex under fluoroscopic guidance. The electrode tip was screwed into the endocardium by rotation of the entire lead. After confirming a right ventricular apical location, right ventricular endocardial pacing and sensing was then performed with the intramyocardial lead.
Example 4 — Results
Ventricular pacing and sensing lead function are summarized in Table 1. For the novel intramyocardial lead, the average R wave at ventricular sites was 7.2 mV, compared to an average R wave of 8.4 mV for the standard active fixation lead placed at identical sites. The average pacing threshold was 0.7 mA at 0.2 msec for the novel lead compared to 1.1 mA for the standard lead. Far field P waves were not recorded on the novel lead; the mean far-field P-wave on the standard lead was 0.7 mV. With the standard lead, phrenic stimulation was seen at threshold (cathode distal) and at 3 mA (cathode proximal electrode). No phrenic stimulation was seen despite outputs up to 20 mA and sites located 3-5 mm from the phrenic nerve. Table 1. Ventricular lead function
The results of lead placement at the right atrial appendage base are shown in Table 2. The average atrial electrogram for the intramyocardial lead measured 1.7 mV; far-field R-waves were not present (amplitude 0 mV). Using the standard pacing lead, the atrial electrogram amplitude average measured 1.9 mV; the average far-field R-wave was 1.6 mV. Phrenic stimulation occurred with both polarities using the standard lead, and with neither polarity using the novel intramyocardial lead.
10
Table 2. Atrial lead function
There were no complications associated with intramyocardial lead use. Specifically, there was no evidence of electrode short-circuiting, and no evidence of significant myocardial injury (as determined by absence of ectopy, the sensed electrogram, and visual inspection of the myocardium). The screw-in electrodes remained intramyocardial and did not penetrate beyond the epicardium.
These experiments demonstrate that intramyocardial pacing is feasible and results in site-specific pacing and sensing function. The types of leads described herein may eliminate far-field signal oversensing and phrenic stimulation.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. An electrical lead comprising: a lead body, wherein said lead body has a proximal end and a distal end, wherein said lead body comprises at least two conductors; and at least two electrodes, wherein said at least two electrodes are disposed at said distal end of said lead body, wherein said at least two electrodes have a proximal end and a distal end, wherein said proximal ends of said at least two electrodes are electrically connected to said distal ends of said at least two conductors, wherein said at least two electrodes comprise an inner electrode and an outer electrode, wherein said outer electrode is helical shaped and has an inside-the-helix surface and an outside-the-helix surface.
2. The electrical lead of claim 1 , wherein said inner electrode is linear shaped.
3. The electrical lead of claim 2, wherein said inner lead is at least partially coated with a non-conductive material.
4. The electrical lead of claim 1 , wherein said inner electrode is helical shaped and has an inside-the-helix surface and an outside-the-helix surface.
5. The bipolar pacing lead of claim 1 , wherein said inside-the-helix surface of said outer electrode is coated with a non-conductive material.
6. The bipolar pacing lead of claim 1, wherein said outside-the-helix surface of said outer electrode is coated with a non-conductive material.
7. The bipolar pacing lead of claim 4, wherein said inside-the-helix surface of said inner electrode is coated with a non-conductive material.
8. The bipolar pacing lead of claim 4, wherein said outside-the-helix surface of said inner electrode is coated with a non-conductive material.
9. The electrical lead of claim 1, wherein said inner electrode and said outer electrode are co-axial at said proximal ends of said electrodes.
10. The electrical lead of claim 1 , wherein the overall length of said electrical lead is about 3 mm to about 7 mm.
11. The electrical lead of claim 1, wherein said conductors are coaxial with one another.
12. The electrical lead of claim 1, wherein said conductors are parallel to one another.
13. The electrical lead of claim 1 , wherein said inner electrode and said outer electrode are bipolar.
EP06817078A 2005-12-22 2006-10-17 Helical electrodes for intramyocardial pacing and sensing Withdrawn EP1968690A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75309805P 2005-12-22 2005-12-22
PCT/US2006/040613 WO2007073435A1 (en) 2005-12-22 2006-10-17 Helical electrodes for intramyocardial pacing and sensing

Publications (2)

Publication Number Publication Date
EP1968690A1 true EP1968690A1 (en) 2008-09-17
EP1968690A4 EP1968690A4 (en) 2009-02-18

Family

ID=38188994

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06817078A Withdrawn EP1968690A4 (en) 2005-12-22 2006-10-17 Helical electrodes for intramyocardial pacing and sensing

Country Status (2)

Country Link
EP (1) EP1968690A4 (en)
WO (1) WO2007073435A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008005378B4 (en) * 2008-01-22 2010-11-25 Osypka, Peter, Dr.- Ing. Implantable bipolar electrode
US8903514B2 (en) * 2009-11-30 2014-12-02 St. Jude Medical Ab Medical implantable lead with fixation detection
EP2773419B1 (en) 2011-11-04 2019-02-27 Shanghai MicroPort Medical (Group) Co., Ltd. Implantable passive medical lead
US9199072B2 (en) 2011-11-04 2015-12-01 Shanghai Microport Medical (Group) Co., Ltd. Implantable medical lead
WO2013063796A1 (en) 2011-11-04 2013-05-10 Shanghai Microport Medical (Group) Co., Ltd. Implantable active medical lead
US9278210B2 (en) 2012-06-28 2016-03-08 Shanghai Microport Medical (Group) Co., Ltd. Bipolar active cardiac electrical lead
WO2014000234A1 (en) 2012-06-28 2014-01-03 Shanghai Microport Medical (Group) Co., Ltd. Assembly of passive cardiac electrical lead
CN103648580B (en) 2012-06-28 2016-08-17 上海微创医疗器械(集团)有限公司 The assembling of active cardiac electrical lead
US8948883B2 (en) * 2013-04-24 2015-02-03 Medtronic, Inc. Electrode assemblies and associated fixation members for implantable medical devices
US10905886B2 (en) 2015-12-28 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device for deployment across the atrioventricular septum
US10668294B2 (en) 2016-05-10 2020-06-02 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker configured for over the wire delivery
US11207527B2 (en) 2016-07-06 2021-12-28 Cardiac Pacemakers, Inc. Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US10688304B2 (en) 2016-07-20 2020-06-23 Cardiac Pacemakers, Inc. Method and system for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system
EP3500342B1 (en) 2016-08-19 2020-05-13 Cardiac Pacemakers, Inc. Trans-septal implantable medical device
WO2018057626A1 (en) 2016-09-21 2018-03-29 Cardiac Pacemakers, Inc. Implantable cardiac monitor
EP3515553B1 (en) 2016-09-21 2020-08-26 Cardiac Pacemakers, Inc. Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery
US10758737B2 (en) 2016-09-21 2020-09-01 Cardiac Pacemakers, Inc. Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter
WO2018081133A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Implantable medical device having a sense channel with performance adjustment
CN109890457B (en) 2016-10-27 2023-07-04 心脏起搏器股份公司 Use of a separate device for managing pacing pulse energy of a cardiac pacemaker
US10413733B2 (en) 2016-10-27 2019-09-17 Cardiac Pacemakers, Inc. Implantable medical device with gyroscope
US10765871B2 (en) 2016-10-27 2020-09-08 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
WO2018081225A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Implantable medical device delivery system with integrated sensor
WO2018081721A1 (en) 2016-10-31 2018-05-03 Cardiac Pacemakers, Inc Systems for activity level pacing
WO2018081713A1 (en) 2016-10-31 2018-05-03 Cardiac Pacemakers, Inc Systems for activity level pacing
US10583301B2 (en) 2016-11-08 2020-03-10 Cardiac Pacemakers, Inc. Implantable medical device for atrial deployment
CN109952129B (en) 2016-11-09 2024-02-20 心脏起搏器股份公司 System, device and method for setting cardiac pacing pulse parameters for a cardiac pacing device
AU2018213326B2 (en) 2017-01-26 2020-09-10 Cardiac Pacemakers, Inc. Intra-body device communication with redundant message transmission
EP3573708B1 (en) 2017-01-26 2021-03-10 Cardiac Pacemakers, Inc. Leadless implantable device with detachable fixation
US10905872B2 (en) 2017-04-03 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device with a movable electrode biased toward an extended position
EP3606605B1 (en) 2017-04-03 2023-12-20 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate
WO2019036568A1 (en) 2017-08-18 2019-02-21 Cardiac Pacemakers, Inc. Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator
EP3668592B1 (en) 2017-08-18 2021-11-17 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
WO2019060302A1 (en) 2017-09-20 2019-03-28 Cardiac Pacemakers, Inc. Implantable medical device with multiple modes of operation
US11185703B2 (en) 2017-11-07 2021-11-30 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker for bundle of his pacing
US11260216B2 (en) 2017-12-01 2022-03-01 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker
WO2019108830A1 (en) 2017-12-01 2019-06-06 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with reversionary behavior
WO2019108482A1 (en) 2017-12-01 2019-06-06 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker
WO2019108837A1 (en) 2017-12-01 2019-06-06 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker
US11529523B2 (en) 2018-01-04 2022-12-20 Cardiac Pacemakers, Inc. Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone
US10874861B2 (en) 2018-01-04 2020-12-29 Cardiac Pacemakers, Inc. Dual chamber pacing without beat-to-beat communication
EP3768160B1 (en) 2018-03-23 2023-06-07 Medtronic, Inc. Vfa cardiac therapy for tachycardia
US11235159B2 (en) 2018-03-23 2022-02-01 Medtronic, Inc. VFA cardiac resynchronization therapy
EP3768369A1 (en) 2018-03-23 2021-01-27 Medtronic, Inc. Av synchronous vfa cardiac therapy
WO2020065582A1 (en) 2018-09-26 2020-04-02 Medtronic, Inc. Capture in ventricle-from-atrium cardiac therapy
US11951313B2 (en) 2018-11-17 2024-04-09 Medtronic, Inc. VFA delivery systems and methods
US11679265B2 (en) 2019-02-14 2023-06-20 Medtronic, Inc. Lead-in-lead systems and methods for cardiac therapy
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
US11213676B2 (en) 2019-04-01 2022-01-04 Medtronic, Inc. Delivery systems for VfA cardiac therapy
US11712188B2 (en) 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
US11305127B2 (en) 2019-08-26 2022-04-19 Medtronic Inc. VfA delivery and implant region detection
US11813466B2 (en) 2020-01-27 2023-11-14 Medtronic, Inc. Atrioventricular nodal stimulation
US11911168B2 (en) 2020-04-03 2024-02-27 Medtronic, Inc. Cardiac conduction system therapy benefit determination
US11813464B2 (en) 2020-07-31 2023-11-14 Medtronic, Inc. Cardiac conduction system evaluation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355642A (en) * 1980-11-14 1982-10-26 Physio-Control Corporation Multipolar electrode for body tissue
US5545201A (en) * 1995-03-29 1996-08-13 Pacesetter, Inc. Bipolar active fixation lead for sensing and pacing the heart
US5755764A (en) * 1996-09-10 1998-05-26 Sulzer Intermedics Inc. Implantable cardiac stimulation catheter
US20040068299A1 (en) * 2002-10-02 2004-04-08 Laske Timothy G. Active fluid delivery catheter

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577643A (en) * 1984-05-10 1986-03-25 Cordis Corporation Movable multi-contact electromechanical connection
US4662382A (en) * 1985-01-16 1987-05-05 Intermedics, Inc. Pacemaker lead with enhanced sensitivity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355642A (en) * 1980-11-14 1982-10-26 Physio-Control Corporation Multipolar electrode for body tissue
US5545201A (en) * 1995-03-29 1996-08-13 Pacesetter, Inc. Bipolar active fixation lead for sensing and pacing the heart
US5755764A (en) * 1996-09-10 1998-05-26 Sulzer Intermedics Inc. Implantable cardiac stimulation catheter
US20040068299A1 (en) * 2002-10-02 2004-04-08 Laske Timothy G. Active fluid delivery catheter

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007073435A1 *

Also Published As

Publication number Publication date
EP1968690A4 (en) 2009-02-18
WO2007073435A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EP1968690A1 (en) Helical electrodes for intramyocardial pacing and sensing
US20080294229A1 (en) Helical Electrodes for Intramyocardial Pacing and Sensing
US6937897B2 (en) Electrode for His bundle stimulation
US20180361145A1 (en) Steerable epicardial pacing catheter system placed via the subxiphoid process
US9579501B2 (en) His bundle lead delivery system
JP5154692B2 (en) His bundle stimulation system
US5755765A (en) Pacing lead having detachable positioning member
US7389148B1 (en) Electrode design for defibrillation and/or sensing capabilities
US9072890B2 (en) Pacing, sensing or defibrillator leads for implantation into the myocardium
US7177704B2 (en) Pacing method and apparatus
US7801622B2 (en) Medical electrical lead and delivery system
US5643338A (en) Single-pass A-V lead for pacing with stimulation of right ventricular outflow tract
US20200276439A1 (en) Shaped epicardial lead and placement system and method
US9987484B2 (en) Method and system for lead delivery
US20070293923A1 (en) Lead with orientation feature
JP2006507086A (en) System for delivering implantable medical devices intravenously
US20230218906A1 (en) Systems, devices, and methods for his bundle cardiac pacing
US11654278B1 (en) Cardiac pacing lead
CN116726398A (en) Lead of cardiac conduction system with defibrillation function
US11446486B1 (en) Multielectrode medical lead

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090115

17Q First examination report despatched

Effective date: 20090424

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 1/05 20060101AFI20140930BHEP

INTG Intention to grant announced

Effective date: 20141105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150317